β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis

  • Michael D. Thompson
  • , Akshata Moghe
  • , Pamela Cornuet
  • , Rebecca Marino
  • , Jianmin Tian
  • , Pengcheng Wang
  • , Xiaochao Ma
  • , Marc Abrams
  • , Joseph Locker
  • , Satdarshan P. Monga
  • , Kari Nejak-Bowen

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Abstract

Cholestatic liver diseases result from impaired bile flow and are characterized by inflammation, atypical ductular proliferation, and fibrosis. The Wnt/β-catenin pathway plays a role in bile duct development, yet its role in cholestatic injury remains indeterminate. Liver-specific β-catenin knockout mice and wild-type littermates were subjected to cholestatic injury through bile duct ligation or short-term exposure to 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet. Intriguingly, knockout mice exhibit a dramatic protection from liver injury, fibrosis, and atypical ductular proliferation, which coincides with significantly decreased total hepatic bile acids (BAs). This led to the discovery of a role for β-catenin in regulating BA synthesis and transport through regulation of farnesoid X receptor (FXR) activation. We show that β-catenin functions as both an inhibitor of nuclear translocation and a nuclear corepressor through formation of a physical complex with FXR. Loss of β-catenin expedited FXR nuclear localization and FXR/retinoic X receptor alpha association, culminating in small heterodimer protein promoter occupancy and activation in response to BA or FXR agonist. Conversely, accumulation of β-catenin sequesters FXR, thus inhibiting its activation. Finally, exogenous suppression of β-catenin expression during cholestatic injury reduces β-catenin/FXR complex activation of FXR to decrease total BA and alleviate hepatic injury. Conclusion: We have identified an FXR/β-catenin interaction whose modulation through β-catenin suppression promotes FXR activation and decreases hepatic BAs, which may provide unique therapeutic opportunities in cholestatic liver diseases. (Hepatology 2018;67:955–971).

Original languageEnglish (US)
Pages (from-to)955-971
Number of pages17
JournalHepatology
Volume67
Issue number3
DOIs
StatePublished - Mar 2018

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis'. Together they form a unique fingerprint.

Cite this